CHARLOTTE, N.C., Feb. 14, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 13th Annual BIO CEO & Investor Conference at 1:30 PM ET on Monday, February 14th at the Waldorf Astoria Hotel in New York City.
In addition to a brief overview of the company's product pipeline, clinical development status and key upcoming milestones, Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, will review the preliminary results from Study 306a, Chelsea's Phase III trial of Droxidopa in neurogenic orthostatic hypotension associated with Parkinson's disease.
Dr. Pedder's presentation will be webcast live and archived for 90 days on Chelsea's website, .
About Chelsea Therapeutics
Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea's most advanced drug candidate, NORTHERA™ (droxidopa), is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).
This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include our need to raise operating capital, our history of losses, risks and costs of drug development, risk of regulatory approvals, our reliance on our lead drug candidates Droxidopa and CH-1504, reliance on collaborations and licenses, intellectual property risks, competition, market acceptance for our products if any are approved for marketing and reliance on key personnel including specifically Dr. Pedder.
CONTACT: Investors: Kathryn McNeil Chelsea Therapeutics 718-788-2856 email@example.com